Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)

Contineum Therapeutics (CTNM) has 1 years of Amortization of Deferred Charges data on record, last reported at -$1000.0 in Q4 2023.

  • For Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to -$1000.0; the TTM value through Sep 2024 reached -$1000.0, changed N/A, while the annual FY2023 figure was -$198000.0, N/A changed from the prior year.
  • Amortization of Deferred Charges reached -$1000.0 in Q4 2023 per CTNM's latest filing, up from -$223000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $26000.0 in Q1 2023 and bottomed at -$223000.0 in Q2 2023.